• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

AAL-993

CAS No. 269390-77-4

AAL-993 ( —— )

产品货号. M27434 CAS No. 269390-77-4

AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥721 有现货
10MG ¥1199 有现货
25MG ¥2341 有现货
50MG ¥3686 有现货
100MG ¥5443 有现货
500MG ¥11583 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    AAL-993
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.
  • 产品描述
    AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on other tyrosine kinases. AAL993 also shows potent antiangiogenic and antitumor activities.(In Vitro):AAL993 suppressed HIF-1α expression through the inhibition of ERK without affecting Akt phosphorylation.(In Vivo):AAL993 (24-100 mg/kg; p.o.) inhibited both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases in B16 melanoma xenograft model. AAL993 potently inhibited VEGF-induced angiogenesis with an ED50 value of 7 mg/kg in an implant model.
  • 同义词
    ——
  • 通路
    Angiogenesis
  • 靶点
    VEGFR
  • 受体
    ROS;Beta Amyloid
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    269390-77-4
  • 分子量
    371.4
  • 分子式
    C20H16F3N3O
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    FC(F)(F)c1cccc(NC(=O)c2ccccc2NCc2ccncc2)c1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Gül?in I, et al. Antioxidant activity of saponins isolated from ivy: alpha-hederin, hederasaponin-C, hederacolchiside-E and hederacolchiside-F. Planta Med. 2004 Jun;70(6):561-3.
产品手册
关联产品
  • Ranibizumab

    Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.

  • Fruquintinib

    A potent and highly selective small molecule inhibitor of VEGFR1/2/3 with IC50 of 33/3/5/0.5 nM, respectively.

  • Lenvatinib mesylate

    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.